Image
Multimedia

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Clinical Practice Guidelines

The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.

Chalasani N, et al. Hepatology. 2018;67(1):328-357.

Clinical Resources

Histological Scoring System for Nonalcoholic Fatty Liver Disease.

Transplant Pathology Internet Services, 2009.

NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score.

MD+CALC online calculator, 2016.

Patient Resources

American College of Gastroenterology (ACG) Patient Education and Resource Center.

The ACG website. provides a basic overview of NAFLD and includes patient-centered podcasts.

American Liver Foundation.

The American Liver Foundation website offers broad-based information and links to additional educational resources and support services for patients living with liver disease.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Health Information Center.

The NIDDK website for NAFLD and nonalcoholic steatohepatitis (NASH) provides comprehensive patient-centered information and resources, including an overview of clinical trial participation.

Suggested Readings

Non-alcoholic fatty liver disease: an expanded review.

Benedict M, Zhang X. World J Hepatol. 2017;9(16):715-732.

Nonalcoholic fatty liver disease.

Brunt EM, et al. Nat Rev Dis Primers. 2015;1:15080.

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Buzzetti E, et al. Metabolism. 2016;65(8):1038-1048.

The natural course of non-alcoholic fatty liver disease.

Calzadilla Bertot L, Adams LA. Int J Mol Sci. 2016;17(5):E774.

Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.

Cusi K, et al. Ann Intern Med. 2016;165(5):305-315.

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, et al. Hepatology. 2017;67(5):1754-1767.

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).

Golabi P, et al. Medicine (Baltimore). 2018;97(13):e0214.

Pharmacotherapy for NASH: current and emerging.

Konerman MA, Jones JC, Harrison SA. J Hepatol. 2018;68(2):362-375.

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.

Loomba R, et al. Hepatology. 2018;67(2):549-559.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.

The therapeutic landscape of non-alcoholic steatohepatitis.

Perazzo H, Dufour JF. Liver Int. 2017;37(5):634-647.

Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.

Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.

Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR study.

Ratziu V, et al. J Hepatol. 2018;68(suppl 1):S1-S2.

Nonalcoholic fatty liver disease: a systematic review.

Rinella ME. JAMA. 2015;313(22):2263-2273.

Management of NAFLD: a stage-based approach.

Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.

Treatment of NAFLD with diet, physical activity and exercise.

Romero-Gómez M, et al. J Hepatol. 2017;67(4):829-846.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Sanyal AJ, et al. N Engl J Med. 2010;362(18):1675-1685.

Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.

Tapper EB, Loomba R. Nat Rev Gastroenterol Hepatol. 2018;15(5):274-282.

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.

Wong VW, et al. Hepatology. 2010;51(2):454-462.

Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes.

Younossi ZM, et al. Hepatology. 2016;64(1):73-84.

Activity
The Big (& Small) Picture of NASH

Building Your Understanding to Combat a Growing Problem

Relevant Resources

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

The Changing Landscape of IBD

Emerging Concepts in Patient Management

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today